<DOC>
	<DOCNO>NCT01940510</DOCNO>
	<brief_summary>This single center , open-label , 3-period , fixed-sequence study evaluate effect multiple oral dos rifampin pharmacokinetics single oral dose RO5424802 healthy volunteer . Subjects receive single dose RO5424802 Days 1 17 rifampin daily Days 8 Day 20 .</brief_summary>
	<brief_title>A Study Effect Multiple Doses Rifampin Single Dose Pharmacokinetics RO5424802</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male female volunteer , 18 55 year age inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination Body mass index ( BMI ) 18 32 kg/m2 inclusive Nonsmoking subject former smoking subject ( smoke past six month first dose ) Female subject must surgically sterile postmenopausal past year Male subject partner childbearing potential must willing use two effective method contraception , one must barrier method ( e.g. , condom ) study 90 day last drug administration Women childbearing potential , pregnant lactate woman , male female partner pregnant lactate Positive urine test drug abuse , alcohol , cotinine test screen prior admission study unit Suspicion regular consumption drug ( ) abuse include marijuana Current smoker subject discontinue smoke less six month prior first dose History ( within three month Screening ) alcohol consumption exceed 2 standard drink per day average ( 1 standard drink = 10 gram alcohol ) . Alcohol consumption prohibit 72 hour prior entry clinical site center throughout entire study ( include washout period ) discharge Positive hepatitis B , hepatitis C , HIV infection Participation investigational drug device study within 45 day 5 halflives ( whichever time period longer ) 6 month biologic therapy prior first dose Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , absorption , distribution , metabolism excretion study medication , would , opinion PI , pose unacceptable risk subject study History hypersensitivity additives RO5424802 formulation ( lactose monohydrate , microcrystalline cellulose , sodium starch glycolate , hydroxypropyl cellulose , sodium lauryl sulphate , magnesium stearate ) Any history hypersensitivity contraindication use rifampin rifamycins history severe drugrelated allergic reaction hepatoxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>